跳至主要内容
临床试验/NCT06419478
NCT06419478终止不适用

Exploring Early Postoperative Core Symptoms in Chinese Patients With Primary Liver Cancer: a Cross-sectional and Longitudinal Network Analysis

Mengmeng Yuan1 个研究点 分布在 1 个国家目标入组 249 人开始时间: 2021年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
249
试验地点
1
主要终点
MD Anderson Symptom Inventory

研究概览

简要总结

Patients with primary liver cancer (PLC) experience a range of symptoms in the early postoperative period. Symptoms include cancer-related symptoms and adverse effects of treatment. Exploring the core symptoms and their dynamics in the early post-hepatectomy patients may help provide better symptom management programs. The purpose of this study was to identify the core symptoms in early post-hepatectomy patients and to explore the trajectory of their dynamics. During the period from March 2021 to September 2022, a total of 281 patients diagnosed with PLC and undergoing radical curative surgery were recruited from the hepatobiliary surgery departments of two hospitals in Eastern China, among whom 249 individuals (88.60%) agreed to participate in the study. A comprehensive symptom assessment was administered to the patients 1-2 days after surgery (T1) and 1-2 days before discharge (T2). Network analysis was used to identify core symptoms in early post-hepatectomy patients based on symptom severity.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Cross Sectional

入排标准

年龄范围
40 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eligible patients were ≥18 years of age; had a diagnosis of primary liver cancer based on pathologic examination; were receiving the first hepatectomy; were conscious, spoke Chinese, and had basic communication skills.

排除标准

  • Exclusion criteria include concurrent malignant tumors, mental disorders, or consciousness impairments, as well as participation in other clinical interventions.

结局指标

主要结局

MD Anderson Symptom Inventory

时间窗: 1-2 days after surgery (T1) and 1-2 days before discharge (T2).

The MD Anderson Symptom Inventory (MDASI) is one of the most widely used symptom assessment tools for cancer patients in clinical and research settings and is used to evaluate the severity of symptoms and their impact on daily life. It consists of 13 core symptom items and 6 symptom interference items. The severity of each symptom is rated on an 11-point Likert scale (0 = "not at all" and 10 = "as bad as you can imagine"). The MDASI-C, a Chinese version translated in 2004 by Wang et al., has good reliability, with a Cronbach's alpha of 0.82-0.94.

次要结局

  • Symptom Module Specific for Primary Liver Cancer(1-2 days after surgery (T1) and 1-2 days before discharge (T2).)

研究者

发起方
Mengmeng Yuan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mengmeng Yuan

Research Assistant

Anhui Medical University

研究点 (1)

Loading locations...

相似试验